查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1298581

孤儿药市场：2023-2028年全球行业趋势、份额、规模、增长、机会和预测

Orphan Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3个工作天内

价格

2022年，全球孤儿药市场规模达到1917亿美元。展望未来，IMARC集团预计到2028年市场规模将达到3835亿美元，在2023-2028年期间表现出12.02%的增长率（CAGR）。

孤儿药指的是用于诊断、预防和治疗罕见医疗疾病的医药产品。这些药物的生产是为了满足特定的公共卫生要求，通常市场有限，因为它们是为少数病人生产的。它们对众多肿瘤、代谢、血液学、免疫学、传染病和神经系统疾病有效。医学上的疾病，如淋巴瘤、白血病、囊性纤维化、胶质瘤、胰腺癌、卵巢癌、多发性骨髓瘤和肾细胞癌等，往往是威胁生命的慢性疾病，是进行性的，是退化性的，是致残性的，需要对其特殊症状有效的特定治疗方案。

孤儿药市场趋势：

癌症和其他罕见遗传性疾病的发病率越来越高，这是推动市场增长的关键因素之一。制药商正在开发创新的孤儿药，为患者提供个性化的治疗。群众对孤儿药好处的认识不断提高，也推动了市场的发展。新的制药厂家的出现和政府为抑制传染病的传播而实施的有利政策也促进了市场的增长。此外，各种产品创新，如生物孤儿药的开发，正在成为其他增长的诱导因素。这些药物可以治疗疾病，如癌症，并扭转对干细胞造成的损害，这大大促进了它们的整体需求。其他因素，包括医疗基础设施的改善，以及广泛的研究和开发（R&D）活动，预计将进一步推动市场。

目录

第一章：前言

第二章：范围和方法

  • 研究的目标
  • 利益相关者
  • 数据来源
    • 主要来源
    • 二级来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球孤儿药市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：按药物类型分類的市场

  • 生物类
    • 市场趋势
    • 市场预测
  • 非生物类
    • 市场趋势
    • 市场预测

第7章 ：按疾病类型分類的市场

  • 肿瘤学
    • 市场趋势
    • 市场预测
  • 血液学
    • 市场趋势
    • 市场预测
  • 神经内科
    • 市场趋势
    • 市场预测
  • 心血管科
    • 市场趋势
    • 市场预测
  • 其他市场
    • 市场趋势
    • 市场预测

第8章：按阶段分類的市场

  • 第一阶段
    • 市场趋势
    • 市场预测
  • 第二阶段
    • 市场趋势
    • 市场预测
  • 第三阶段
    • 市场趋势
    • 市场预测
  • 第四阶段
    • 市场趋势
    • 市场预测

第九章：按最畅销药物分類的市场

  • Revlimid
    • 市场趋势
    • 市场预测
  • 利妥昔单抗
    • 市场趋势
    • 市场预测
  • 科帕酮
    • 市场趋势
    • 市场预测
  • 欧狄沃
    • 市场趋势
    • 市场预测
  • 凯特鲁达
    • 市场趋势
    • 市场预测
  • 英布罗维卡
    • 市场趋势
    • 市场预测
  • 阿沃尼克斯
    • 市场趋势
    • 市场预测
  • 森西帕
    • 市场趋势
    • 市场预测
  • 润百颜
    • 市场趋势
    • 市场预测
  • 其他
    • 市场趋势
    • 市场预测

第十章：按分销渠道分類的市场

  • 医院药房
    • 市场趋势
    • 市场预测
  • 零售药店
    • 市场趋势
    • 市场预测
  • 网上商店
    • 市场趋势
    • 市场预测
  • 其他
    • 市场趋势
    • 市场预测

第十一章 ：按地区分類的市场

  • 北美洲
    • 美国
      • 市场趋势
      • 市场预测
    • 加拿大
      • 市场趋势
      • 市场预测
  • 亚太地区
    • 中国
      • 市场趋势
      • 市场预测
    • 日本
      • 市场趋势
      • 市场预测
    • 印度
      • 市场趋势
      • 市场预测
    • 韩国
      • 市场趋势
      • 市场预测
    • 澳大利亚
      • 市场趋势
      • 市场预测
    • 印尼
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 欧洲
    • 德国
      • 市场趋势
      • 市场预测
    • 法国
      • 市场趋势
      • 市场预测
    • 英国
      • 市场趋势
      • 市场预测
    • 意大利
      • 市场趋势
      • 市场预测
    • 西班牙
      • 市场趋势
      • 市场预测
    • 俄罗斯
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场趋势
      • 市场预测
    • 墨西哥
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 中东和非洲
    • 市场趋势
    • 按国家分類的市场
    • 市场预测

第十二章：SWOT分析

  • 概述
  • 优势
  • 劣势
  • 机会
  • 威胁

第十三章 ：价值链分析

第十四章：波特斯五力分析

  • 概述
  • 买方的讨价还价能力
  • 供应商的讨价还价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第十五章 ：价格分析

第16章 ：竞争格局

  • 市场结构
  • 主要参与者
  • 主要参与者的概况
    • AbbVie Inc.
    • Alexion Pharmaceuticals Inc.
    • Amgen Inc.
    • Biogen Inc.
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • Jazz Pharmaceuticals Plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd
Product Code: SR112023A2382

The global orphan drugs market size reached US$ 191.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 383.5 Billion by 2028, exhibiting a growth rate (CAGR) of 12.02% during 2023-2028.

Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

Orphan Drugs Market Trends:

The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global orphan drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug type, disease type, phase, top selling drugs and distribution channel.

Breakup by Drug Type:

Biological

Non-Biological

Breakup by Disease Type:

Oncology

Hematology

Neurology

Cardiovascular

Others

Breakup by Phase:

Phase I

Phase II

Phase III

Phase IV

Breakup by Top Selling Drugs:

Revlimid

Rituxan

Copaxone

Opdivo

Keytruda

Imbruvica

Avonex

Sensipar

Soliris

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Stores

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

1. What was the size of the global orphan drugs market in 2022?

2. What is the expected growth rate of the global orphan drugs market during 2023-2028?

3. What are the key factors driving the global orphan drugs market?

4. What has been the impact of COVID-19 on the global orphan drugs market?

5. What is the breakup of the global orphan drugs market based on the drug type?

6. What is the breakup of the global orphan drugs market based on the disease type?

7. What is the breakup of the global orphan drugs market based on top selling drugs?

8. What is the breakup of the global orphan drugs market based on the distribution channel?

9. What are the key regions in the global orphan drugs market?

10. Who are the key players/companies in the global orphan drugs market?

Table of Contents

1   Preface

2   Scope and Methodology 

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global Orphan Drugs Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Drug Type

  • 6.1  Biological
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2  Non-Biological
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7   Market Breakup by Disease Type

  • 7.1  Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  Hematology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3  Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4  Cardiovascular
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5  Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8   Market Breakup by Phase

  • 8.1  Phase I
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2  Phase II
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3  Phase III
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4  Phase IV
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9   Market Breakup by Top Selling Drugs

  • 9.1  Revlimid
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2  Rituxan
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3  Copaxone
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4  Opdivo
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5  Keytruda
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast
  • 9.6  Imbruvica
    • 9.6.1 Market Trends
    • 9.6.2 Market Forecast
  • 9.7  Avonex
    • 9.7.1 Market Trends
    • 9.7.2 Market Forecast
  • 9.8  Sensipar
    • 9.8.1 Market Trends
    • 9.8.2 Market Forecast
  • 9.9  Soliris
    • 9.9.1 Market Trends
    • 9.9.2 Market Forecast
  • 9.10  Others
    • 9.10.1 Market Trends
    • 9.10.2 Market Forecast

10  Market Breakup by Distribution Channel

  • 10.1  Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2  Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3  Online Stores
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4  Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11  Market Breakup by Region

  • 11.1  North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2  Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3  Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4  Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5  Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12  SWOT Analysis

  • 12.1  Overview
  • 12.2  Strengths
  • 12.3  Weaknesses
  • 12.4  Opportunities
  • 12.5  Threats

13  Value Chain Analysis

14  Porters Five Forces Analysis

  • 14.1  Overview
  • 14.2  Bargaining Power of Buyers
  • 14.3  Bargaining Power of Suppliers
  • 14.4  Degree of Competition
  • 14.5  Threat of New Entrants
  • 14.6  Threat of Substitutes

15  Price Analysis

16  Competitive Landscape

  • 16.1  Market Structure
  • 16.2  Key Players
  • 16.3  Profiles of Key Players
    • 16.3.1  AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio 
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2  Alexion Pharmaceuticals Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio 
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3  Amgen Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio 
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4  Biogen Inc.
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio 
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5  Bristol Myers Squibb Company
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio 
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6  F. Hoffmann-La Roche AG (Roche Holding AG)
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio 
      • 16.3.6.3 SWOT Analysis
    • 16.3.7  Jazz Pharmaceuticals Plc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio 
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8  Johnson & Johnson 
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9  Merck & Co. Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio 
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10  Novartis AG
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio 
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11  Pfizer Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio 
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12  Sanofi S.A. 
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio 
      • 16.3.12.3 Financials
      • 16.3.12.4 SWOT Analysis
    • 16.3.13  Takeda Pharmaceutical Company Limited 
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio 
      • 16.3.13.3 Financials
      • 16.3.13.4 SWOT Analysis
    • 16.3.14  Teva Pharmaceutical Industries Ltd
      • 16.3.14.1 Company Overview
      • 16.3.14.2 Product Portfolio 
      • 16.3.14.3 Financials
      • 16.3.14.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2022
  • Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2022
  • Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2022
  • Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2022
  • Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: North America: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: United States: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: China: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: India: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Others: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 86: France: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 96: Others: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 104: Others: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
  • Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
  • Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
  • Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million US$), 2023-2028
  • Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million US$), 2023-2028
  • Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 8: Global: Orphan Drugs Market Structure
  • Table 9: Global: Orphan Drugs Market: Key Players